SPARC revenues decline sharply by 52% in Q4

16:15 EDT 9 May 2018 | PharmaBiz

Sun Pharma Advance Research Co. (SPARC), a research wing of Sun Pharmaceuticals Industries, has suffered another set back during the fourth quarter ended March 2018 and its net sales declined sharply by 52

Original Article: SPARC revenues decline sharply by 52% in Q4

More From BioPortfolio on "SPARC revenues decline sharply by 52% in Q4"